Hogan, Andrew and Gaoatswe, Gadintshware and Lynch, Lydia and Corrigan, Michelle and Woods, Conor and O'Connell, Jean and O'Shea, Donal
(2014)
Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.
Diabetologia, 57.
pp. 781-784.
ISSN 0012-186X
Abstract
Aims/hypothesis Glucagon-like peptide 1 (GLP-1) is a gut
hormone used in the treatment of type 2 diabetes mellitus.
There is emerging evidence that GLP-1 has anti-inflammatory
activity in humans, with murine studies suggesting an effect
on macrophage polarisation. We hypothesised that GLP-1
analogue therapy in individuals with type 2 diabetes mellitus
would affect the inflammatory macrophage molecule soluble
CD163 (sCD163) and adipocytokine profile.
Methods We studied ten obese type 2 diabetes mellitus
patients starting GLP-1 analogue therapy at a hospital-based
diabetes service. We investigated levels of sCD163, TNF-α,
IL-1β, IL-6, adiponectin and leptin by ELISA, before and
after 8 weeks of GLP-1 analogue therapy.
Results GLP-1 analogue therapy reduced levels of the inflammatory macrophage activation molecule sCD163 (220 ng/ml
vs 171 ng/ml, p <0.001). This occurred independent of changes
in body weight, fructosamine and HbA1c. GLP-1 analogue
therapy was associated with a decrease in levels of the inflammatory cytokines TNF-α (264 vs 149 pg/ml, p <0.05), IL-1β
(2,919 vs 748 pg/ml, p <0.05) and IL-6 (1,379 vs 461 pg/ml
p <0.05) and an increase in levels of the anti-inflammatory
adipokine adiponectin (4,480 vs 6,290 pg/ml, p <0.002).
Conclusions/interpretation In individuals with type 2 diabetes mellitus, GLP-1 analogue therapy reduces the frequency of
inflammatory macrophages. This effect is not dependent on
the glycaemic or body weight effects of GLP-1.
Repository Staff Only(login required)
 |
Item control page |
Downloads per month over past year
Altmetric
Altmetric